Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 28;10(11):2747. doi: 10.3390/biomedicines10112747

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

HSP90 inhibition affects CD4⁺ and CD8⁺ T-cell degranulation responses. Degranulation response, as measured by the surface expression of CD107a on CD4⁺ T cells (A,B) and CD8+ T cells (C,D) in healthy controls and BCL patients. Isolated T cells were stimulated with allogeneic mo-DCs (A,C) or anti-CD3/CD28 (B,D) in the presence or absence of 0.1 µM geldanamycin, 10 µg/mL PD-1 inhibitor (Pembrolizumab/Nivolumab), 10 µg/mL CTLA-4 inhibitor (Ipilimumab). (E) Representative flow cytometry plots showing a decrease in CD107a expression on CD4⁺ and CD8⁺ T cells in healthy controls following HSP90 inhibition. Data are presented as mean ± SEM. * p < 0.05.

HSP90 inhibition affects CD4⁺ and CD8⁺ T-cell degranulation responses. Degranulation response, as measured by the surface expression of CD107a on CD4⁺ T cells (A,B) and CD8+ T cells (C,D) in healthy controls and BCL patients. Isolated T cells were stimulated with allogeneic mo-DCs (A,C) or anti-CD3/CD28 (B,D) in the presence or absence of 0.1 µM geldanamycin, 10 µg/mL PD-1 inhibitor (Pembrolizumab/Nivolumab), 10 µg/mL CTLA-4 inhibitor (Ipilimumab). (E) Representative flow cytometry plots showing a decrease in CD107a expression on CD4⁺ and CD8⁺ T cells in healthy controls following HSP90 inhibition. Data are presented as mean ± SEM. * p < 0.05.